Mitsubishi Tanabe Pharma Corp. is buying Israel-based Neuroderm Ltd., the developer of a belt-worn pump for the continuous delivery of liquid levodopa/carbidopa to treat severe Parkinson's disease (PD), for $1.1 billion in cash, or $39 per share.